Read by QxMD icon Read


Christopher J Coroneos, Jesse C Selber, Anaeze C Offodile, Charles E Butler, Mark W Clemens
OBJECTIVE: To analyze the long-term safety and efficacy outcomes of patients with breast implants. SUMMARY BACKGROUND DATA: Research is ongoing regarding the safety of silicone breast implants. Despite the number of patients with breast implants followed by United States Food and Drug Administration large postapproval studies (LPAS), this database has not been thoroughly analyzed or reported. METHODS: This is a multicentered, cohort study...
January 2019: Annals of Surgery
Camille Laurent, Corinne Haioun, Pierre Brousset, Philippe Gaulard
PURPOSE OF REVIEW: Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare form of lymphoma arising adjacent to a breast implant. We aim to review the pathogenesis and clinico-biological features of BI-ALCL. RECENT FINDINGS: BI-ALCL is a new provisional entity in the 2017 updated WHO classification. Among several hypotheses, BI-ALCL development seems to be determined by the interaction of immune response related to implant products and additional genetic events...
September 2018: Current Opinion in Oncology
Ivonne A Montes-Mojarro, Julia Steinhilber, Irina Bonzheim, Leticia Quintanilla-Martinez, Falko Fend
Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis. The recognition of anaplastic lymphoma kinase (ALK) fusion proteins as a result of chromosomal translocations or inversions was the starting point for the distinction of different subgroups of ALCL. According to their distinct clinical settings and molecular findings, the 2016 revised World Health Organization (WHO) classification recognizes four different entities: systemic ALK-positive ALCL (ALK+ ALCL), systemic ALK-negative ALCL (ALK− ALCL), primary cutaneous ALCL (pC-ALCL), and breast implant-associated ALCL (BI-ALCL), the latter included as a provisional entity...
April 4, 2018: Cancers
Maria C Ferrufino-Schmidt, L Jeffrey Medeiros, Hui Liu, Mark W Clemens, Kelly K Hunt, Camille Laurent, Julian Lofts, Mitual B Amin, Siaw Ming Chai, Angela Morine, Arianna Di Napoli, Ahmet Dogan, Vinita Parkash, Govind Bhagat, Denise Tritz, Andres E Quesada, Sergio Pina-Oviedo, Qinlong Hu, Francisco J Garcia-Gomez, Juan Jose Borrero, Pedro Horna, Beenu Thakral, Marina Narbaitz, R Condon Hughes, Li-Jun Yang, Jonathan R Fromm, David Wu, Da Zhang, Aliyah R Sohani, John Hunt, Indira U Vadlamani, Elizabeth A Morgan, Judith A Ferry, Reka Szigeti, Juan C Tardio, Rosario Granados, Susanne Dertinger, Felix A Offner, Andreas Pircher, Jeff Hosry, Ken H Young, Roberto N Miranda
Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare T-cell lymphoma that arises around breast implants. Most patients manifest with periprosthetic effusion, whereas a subset of patients develops a tumor mass or lymph node involvement (LNI). The aim of this study is to describe the pathologic features of lymph nodes from patients with BI-ALCL and assess the prognostic impact of LNI. Clinical findings and histopathologic features of lymph nodes were assessed in 70 patients with BI-ALCL...
March 2018: American Journal of Surgical Pathology
Arianna Di Napoli, Giuseppina Pepe, Enrico Giarnieri, Claudia Cippitelli, Adriana Bonifacino, Mauro Mattei, Maurizio Martelli, Carlo Falasca, Maria Christina Cox, Iolanda Santino, Maria Rosaria Giovagnoli
Late breast implant seroma may be the presentation of a breast implant-associated anaplastic large cell lymphoma (BI-ALCL), which claims for a prompt recognition. However, BI-ALCL diagnosis on fine-needle aspiration (FNA) might be challenging for pathologists lacking experience with peri-implant breast effusions. Sixty-seven late breast implant seromas collected by FNA from 50 patients were evaluated by Papanicolaou smear stain and immunocytochemistry on cell blocks. A diagnostic algorithm based on the cellular composition, cell morphology and percentage of CD30+ cells was developed...
2017: PloS One
I Kaartinen, K Sunela, J Alanko, K Hukkinen, M-L Karjalainen-Lindsberg, C Svarvar
Breast lymphomas comprise a rare group of malignant breast tumors. Among these, a new entity has emerged as a potentially under-diagnosed disease. Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) most often manifests as a late periprosthetic effusion between 1 and 10 years after the implantation of silicone or saline-filled breast prostheses. BI-ALCL is an anaplastic lymphoma kinase-negative T-cell lymphoma that has a distinctively different clinical course than other breast lymphomas or ALCLs...
August 2017: European Journal of Surgical Oncology
Sevan Evren, Thaer Khoury, Vishalla Neppalli, Helen Cappuccino, Francisco J Hernandez-Ilizaliturri, Prasanna Kumar
BACKGROUND Anaplastic large cell lymphomas (ALCL) are a rare type of primary breast lymphoma. The association between breast implants and ALCL was first described in 1997 and since then 34-173 cases have been presented. The annual incidence of breast implant-associated ALCL (BI-ALCL) is 0.1-0.3 per 100 000 women who undergo breast reconstruction, and cases are often underreported due to the rarity of these tumors. BI-ALCL arises from the inflammatory T cells surrounding the fibrous capsule, and most tumors are in situ...
May 31, 2017: American Journal of Case Reports
Mark W Clemens, Maurizio Bruno Nava, Nicola Rocco, Roberto N Miranda
Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a distinct type of T-cell lymphoma arising around breast implants. The United States FDA recently updated the 2011 safety communication, warning that women with breast implants may have a very low risk of developing ALCL adjacent to a breast implant. According to the World Health Organization, BI-LCL is not a breast cancer or cancer of the breast tissue; it is a lymphoma, a cancer of immune cells. BI-ALCL is highly curable in the majority of patients...
April 2017: Gland Surgery
Henrik Cederleuf, Martin Bjerregård Pedersen, Mats Jerkeman, Thomas Relander, Francesco d'Amore, Fredrik Ellin
Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas...
September 2017: British Journal of Haematology
Rosario Granados, Eva M Lumbreras, Manuel Delgado, José A Aramburu, Juan C Tardío
The cytological examination of peri-prosthetic breast effusions allowed the diagnosis of bilateral breast-implant ALK-negative anaplastic large cell lymphoma (BI-ALCL) in the case reported. Ten years after reconstructive surgery with bilateral breast implants, a large unilateral seroma developed and was cytologically analyzed. The presence of CD30 and CD4-positive large-sized atypical lymphoid cells exhibiting horseshoe-shaped nuclei and a brisk mitotic activity rendered the diagnosis of BI-ALCL. Similar cells were seen in the peri-prosthetic fluid intraoperatively collected from the contralateral breast...
July 2016: Diagnostic Cytopathology
Mark W Clemens, L Jeffrey Medeiros, Charles E Butler, Kelly K Hunt, Michelle A Fanale, Steven Horwitz, Dennis D Weisenburger, Jun Liu, Elizabeth A Morgan, Rashmi Kanagal-Shamanna, Vinita Parkash, Jing Ning, Aliyah R Sohani, Judith A Ferry, Neha Mehta-Shah, Ahmed Dogan, Hui Liu, Nora Thormann, Arianna Di Napoli, Arianna DiNapoli, Stephen Lade, Jorge Piccolini, Ruben Reyes, Travis Williams, Colleen M McCarthy, Summer E Hanson, Loretta J Nastoupil, Rakesh Gaur, Yasuhiro Oki, Ken H Young, Roberto N Miranda
PURPOSE: Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach. PATIENTS AND METHODS: In this study, we applied strict criteria to pathologic findings, assessed therapies used, and conducted a clinical follow-up of 87 patients with BI-ALCL, including 50 previously reported in the literature and 37 unreported...
January 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Hong-Tao Sun, Beibei Xu, Tetsu Yonezawa, Yoshio Sakka, Naoto Shirahata, Minoru Fujii, Jianrong Qiu, Hong Gao
Bi(5)(GaCl(4))(3) sample has been synthesized through the oxidation of Bi metal by gallium chloride (GaCl(3)) salt. Powder X-ray diffraction as well as micro-Raman scattering results revealed that, in addition to crystalline Bi(5)(GaCl(4))(3) in the product, an amorphous phase containing [GaCl(4)](-) and [Ga(2)Cl(7)](-) units also exists. The thorough comparison of steady-state and time-resolved photoluminescent behaviors between the Bi(5)(GaCl(4))(3) product and Bi(5)(AlCl(4))(3) crystal leads us to conclude that Bi(5)(3+) is the dominant emitter in the product, which gives rise to the ultrabroad emission ranging from 1 to 2...
August 28, 2012: Dalton Transactions: An International Journal of Inorganic Chemistry
Matthias F Groh, Anna Isaeva, Michael Ruck
Two polymorphs of the new cluster compound [Ru(2)Bi(14)Br(4)](AlCl(4))(4) have been synthesized from Bi(24)Ru(3)Br(20) in the Lewis acidic ionic liquid [BMIM]Cl/AlCl(3) ([BMIM](+) : 1-n-butyl-3-methylimidazolium) at 140 °C. A large fragment of the precursor's structure, namely the [(Bi(8))Ru(Bi(4)Br(4))Ru(Bi(5))](5+) cluster, dissolved as a whole and transformed into a closely related symmetrical [(Bi(5))Ru(Bi(4)Br(4))Ru(Bi(5))](4+) cluster through structural conversion of a coordinating Bi(8)(2+) to a Bi(5)(+) polycation, while the remainder was left intact...
August 27, 2012: Chemistry: a European Journal
Alexey N Romanov, Zukhra T Fattakhova, Alexander A Veber, Olga V Usovich, Elena V Haula, Vladimir N Korchak, Vladimir B Tsvetkov, Lev A Trusov, Pavel E Kazin, Vladimir B Sulimov
Broadband NIR photoluminescence (from 1000 to 2500 nm) was observed from partially reduced AlCl₃/ZnCl₂/BiCl₃ glass, containing subvalent bismuth species. The luminescence consists of three bands, assigned to Bi⁺ , Bi₂⁴⁺, and Bi₅³⁺ ions. The physical and optical characteristics of these centers and possible contribution to NIR luminescence from bismuth-doped oxide glasses are discussed.
March 26, 2012: Optics Express
Kanishka Biswas, Qichun Zhang, In Chung, Jung-Hwan Song, John Androulakis, Arthur J Freeman, Mercouri G Kanatzidis
The Lewis acidic ionic liquid EMIMBr-AlCl(3) (EMIM = 1-ethyl-3-methylimidazolium) allows a novel synthetic route to the semiconducting layered metal chalcogenides halide [Bi(2)Te(2)Br](AlCl(4)) and its Sb analogue. [Bi(2)Te(2)Br](AlCl(4)) is a direct band gap, strongly anisotropic semiconductor and consists of cationic infinite layers of [Bi(2)Te(2)Br](+) and [AlCl(4)](-) anions inserted between the layers.
October 27, 2010: Journal of the American Chemical Society
Miao Shen, Wei Huang, Wenjuan Zhang, Xiang Hao, Wen-Hua Sun, Carl Redshaw
The stoichiometric reactions of 2-(benzimidazol-2-yl)-6-methylpyridine (L1) or 8-(benzimidazol-2-yl)quinaldine (L2) with trialkylaluminium reagents R(3)Al (R = Me, Et and iBu) afforded the corresponding dialkylaluminium benzimidazolate complexes R(2)AlL (L1, R = Me (1), Et (2), iBu (3); L2 R = Me (4), Et (5), iBu (6)). Treatment of L1 with one or two equivalents of Et(2)AlCl led to the adducts EtAl(L1)(2)·AlEtCl(2) (7) or Et(2)AlL1·AlEtCl(2) (8), respectively. Complex 7 was also available via treatment of 8 with one equivalent of L1...
November 7, 2010: Dalton Transactions: An International Journal of Inorganic Chemistry
María García-Castro, Avelino Martín, Miguel Mena, Carlos Yélamos
Several heterometallic nitrido complexes were prepared by reaction of the imido-nitrido titanium complex [{Ti(eta(5)-C(5)Me(5))(mu-NH)}(3)(mu(3)-N)] (1) with amido derivatives of Group 13-15 elements. Treatment of 1 with bis(trimethylsilyl)amido [M{N(SiMe(3))(2)}(3)] derivatives of aluminum, gallium, or indium in toluene at 150-190 degrees C affords the single-cube amidoaluminum complex [{(Me(3)Si)(2)N}Al{(mu(3)-N)(2)(mu(3)-NH)Ti(3)(eta(5)-C(5)Me(5))(3)(mu(3)-N)}] (2) or the corner-shared double-cube compounds [M(mu(3)-N)(3)(mu(3)-NH)(3){Ti(3)(eta(5)-C(5)Me(5))(3)(mu(3)-N)}(2)] [M = Ga (3), In (4)]...
July 20, 2009: Chemistry: a European Journal
Zenaida Cerimagić, Safet Guska, Bedrudin Banjanović
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin, T-cell lymphoma, representing only 2-3% of all lymphoid neoplasm's in adults according to World Health Organization (WHO). CD30 antigen-positive, large neoplastic cells characterize ALCL. We present here a 46-year-old male with pulmonary ALCL previously diagnosed with Hodgkin disease. Microscopically, atypical bi-and multinucleated cells with frequent mitoses were present. The neoplastic cells were large and had clear cytoplasm, large vesicular nuclei, and prominent nucleoli...
August 2006: Bosnian Journal of Basic Medical Sciences
Qi-hai Gong, Qin Wu, Xie-nan Huang, An-sheng Sun, Jing Nie, Jing-shan Shi
OBJECTIVE: To examine the protective effect of Ginkgo biloba leaf extract (GbE) on learning and memory deficit induced by aluminum chloride (AlCl(3)), and explore its mechanisms. METHODS: The rat models with learning and memory deficit were induced by administering via gastrogavage and drinking of AlCl(3) solution. And the model rats were treated with GbE at the dose of 50, 100, 200 mg/kg every day for 2 months accompanied with drinking of AlCl(3) solution, respectively...
March 2006: Chinese Journal of Integrative Medicine
Emina Torlakovic, Goran Torlakovic, Phuong L Nguyen, Richard D Brunning, Jan Delabie
Whereas L26 (anti-CD20) is well established as a B-cell marker of high specificity for use in paraffin-embedded tissues and JCB117 (anti-CD79a) is increasingly used, a comparable additional pan-B-cell antibody has hitherto not yet been identified. Here we have studied the use of a novel anti-pan-B-cell marker Pax-5 for use in diagnostic pathology. Pax-5 encodes for BSAP (Pax-5), a B-cell-specific transcription factor, the expression of which is detectable as early as the pro-B-cell stage and subsequently in all further stages of B-cell development until the plasma cell stage where it is downregulated...
October 2002: American Journal of Surgical Pathology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"